Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Shanghai Genbase Biotechnology Co. Ltd. currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution is limited to 1 distinct examiner and 1 distinct art unit. This indicates a highly focused technical review for the company's current patent application. The concentration in 1 distinct art unit suggests that the company's research is being evaluated within a specific biological or pharmaceutical sub-discipline.
SABILA, MERCY HELLEN is the busiest examiner, overseeing 1 pending office action. This examiner handles the company's entire current pending workload. With only 1 distinct examiner and 1 pending office action, the company's immediate success in the patent office depends on the outcome of this single case. The lack of multiple pending actions suggests a very specific or limited filing activity in this technology area. Practitioners should focus on the individual examiner's history and the specific standards of the assigned art unit. The absence of examiner diversity means that the company's current prosecution experience is entirely shaped by a single individual's perspective.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SABILA, MERCY HELLEN | 1 | 57.0% | +46.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18038196 | RAS MUTANT EPITOPE PEPTIDE AND T CELL RECEPTOR RECOGNIZING RAS MUTANT | SABILA, MERCY HELLEN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18038196 | RAS MUTANT EPITOPE PEPTIDE AND T CELL RECEPTOR RECOGNIZING RAS MUTANT | SABILA, MERCY HELLEN | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18038196 | RAS MUTANT EPITOPE PEPTIDE AND T CELL RECEPTOR RECOGNIZING RAS MUTANT | SABILA, MERCY HELLEN | 1654 | §103§112 | Non-Final OA | — | Pending | May 22, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial